The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Mycobacterium bovis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mycobacterium bovis

  • For patients with carcinoma in situ the complete-response probability estimates (i.e., the estimated probability of documented disappearance of disease) were 34 percent for doxorubicin (23 of 67 patients) and 70 percent for BCG (45 of 64 patients) (P less than 0.001); the median times to treatment failure were 5.1 and 39 months, respectively [1].
  • Tumour necrosis factor (TNF) was found originally in mouse serum after intravenous injection of bacterial endotoxin into mice primed with viable Mycobacterium bovis, strain Bacillus Calmette-Guerin (BCG) [2].
  • Antibodies to melanoma cell and BCG antigens in sera from tumour-free individuals and from melanoma patients [3].
  • SCID mice infected with the pantothenate auxotroph survived significantly longer (250 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and 35 days, respectively) [4].
  • In contrast, reduced prostaglandin synthesis by macrophages from mice variously treated with the immunologic agents, Corynebacterium parvum or Bacille Calmette Guérin (BCG), closely correlated with enhanced antitoxoplasma activity, one measure of macrophage activation [5].

Psychiatry related information on Mycobacterium bovis

  • Thus, during BCG infection, the B10.A (Bcgr) mice mount an early IFN-gamma response against BCG whereas the B10.A (Bcgs) mice have a delayed IFN-gamma response correlating with their genetic permissiveness expressed as an increased mycobacterial load by day 21 [6].

High impact information on Mycobacterium bovis

  • As compared with intravesical doxorubicin, immunotherapy with BCG provides improved protection against the recurrence of superficial bladder cancer [1].
  • We have found that the eukaryotic-like fas1 gene (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-Cl-PZA when present on multi-copy vectors in M. smegmatis [7].
  • Tumour necrosis factor (TNF) was first described as a factor in the serum of mice injected with tubercle bacilli (BCG) and several days later with lipopolysaccharide (LPS) [8].
  • OBJECTIVE: To determine whether BCG vaccination and age at BCG vaccination are associated with development of atopy [9].
  • CONCLUSIONS: For all study participants, as well as for those being screened for LTBI, the IFN-gamma assay was comparable with the TST in its ability to detect LTBI, was less affected by BCG vaccination, discriminated responses due to nontuberculous mycobacteria, and avoided variability and subjectivity associated with placing and reading the TST [10].

Chemical compound and disease context of Mycobacterium bovis


Biological context of Mycobacterium bovis


Anatomical context of Mycobacterium bovis


Gene context of Mycobacterium bovis

  • Histological examination at 2 and 6 wk after BCG inoculation showed that livers of IFN-gamma R0/0 mice had higher numbers of acid-fast bacteria than wild-type mice, especially at 6 wk [25].
  • Myeloproliferation in BXH-2 mice is concomitant to increased susceptibility to Mycobacterium bovis (BCG) despite the presence of resistance alleles at the Nramp1 locus [26].
  • We have constructed a novel breast cancer vaccine, Bacillus Calmette-Guérin (BCG)-hIL2MUC1, that consists of BCG and expresses a truncated form of MUC1 and human interleukin (IL)-2 [27].
  • However, we and others observed that mice suffering from a bacterial infection, such as Bacillus Calmette-Guérin (BCG), or bearing i.m. some types of tumor, develop a hypersensitivity to the IL-6-inducing and lethal properties of hTNF [28].
  • These findings infer that the essential minimal requirement for TLR2/4-mediated adjuvancy of BCG lies within a modified MDP [29].

Analytical, diagnostic and therapeutic context of Mycobacterium bovis


  1. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. Lamm, D.L., Blumenstein, B.A., Crawford, E.D., Montie, J.E., Scardino, P., Grossman, H.B., Stanisic, T.H., Smith, J.A., Sullivan, J., Sarosdy, M.F. N. Engl. J. Med. (1991) [Pubmed]
  2. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Shirai, T., Yamaguchi, H., Ito, H., Todd, C.W., Wallace, R.B. Nature (1985) [Pubmed]
  3. Antibodies to melanoma cell and BCG antigens in sera from tumour-free individuals and from melanoma patients. Minden, P., Jarrett, C., McClatchy, J.K., Gutterman, J.U., Hersh, E.M. Nature (1976) [Pubmed]
  4. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Sambandamurthy, V.K., Wang, X., Chen, B., Russell, R.G., Derrick, S., Collins, F.M., Morris, S.L., Jacobs, W.R. Nat. Med. (2002) [Pubmed]
  5. Regulation of arachidonic acid metabolism by macrophage activation. Scott, W.A., Pawlowski, N.A., Murray, H.W., Andreach, M., Zrike, J., Cohn, Z.A. J. Exp. Med. (1982) [Pubmed]
  6. Acquired resistance but not innate resistance to Mycobacterium bovis bacillus Calmette-Guérin is compromised by interleukin-12 ablation. Thompson-Snipes, L., Skamene, E., Radzioch, D. Infect. Immun. (1998) [Pubmed]
  7. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Zimhony, O., Cox, J.S., Welch, J.T., Vilchèze, C., Jacobs, W.R. Nat. Med. (2000) [Pubmed]
  8. Antiviral effects of recombinant tumour necrosis factor in vitro. Mestan, J., Digel, W., Mittnacht, S., Hillen, H., Blohm, D., Möller, A., Jacobsen, H., Kirchner, H. Nature (1986) [Pubmed]
  9. BCG vaccination and risk of atopy. Krause, T.G., Hviid, A., Koch, A., Friborg, J., Hjuler, T., Wohlfahrt, J., Olsen, O.R., Kristensen, B., Melbye, M. JAMA (2003) [Pubmed]
  10. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. Mazurek, G.H., LoBue, P.A., Daley, C.L., Bernardo, J., Lardizabal, A.A., Bishai, W.R., Iademarco, M.F., Rothel, J.S. JAMA (2001) [Pubmed]
  11. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. Buzdar, A.U., Blumenschein, G.R., Gutterman, J.U., Tashima, C.K., Hortobagyi, G.N., Smith, T.L., Campos, L.T., Wheeler, W.L., Hersh, E.M., Freireich, E.J., Gehan, E.A. JAMA (1979) [Pubmed]
  12. Failure of isoniazid to cure localized BCG infection. Lorber, B., Vonderheid, E.C., Swenson, R.M., Cundy, K.R. JAMA (1977) [Pubmed]
  13. Adjuvant chemotherapy for stage II and III breast carcinoma. Caprini, J.A., Oviedo, M.A., Cunningham, M.P., Cohen, E., Trueheart, R.S., Khandekar, J.D., Scanlon, E.F. JAMA (1980) [Pubmed]
  14. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Glickman, M.S., Cox, J.S., Jacobs, W.R. Mol. Cell (2000) [Pubmed]
  15. Effect of Corynebacterium parvum, methanol-extraction residue of BCG, and levamisole on macrophage random migration, chemotaxis, and pinocytosis. Sher, N.A., Poplack, D.G., Blaese, R.M., Brown, T.M., Chaparas, S.D. J. Natl. Cancer Inst. (1977) [Pubmed]
  16. Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides. Azad, A.K., Sirakova, T.D., Rogers, L.M., Kolattukudy, P.E. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  17. Insertional mutagenesis and illegitimate recombination in mycobacteria. Kalpana, G.V., Bloom, B.R., Jacobs, W.R. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  18. The effect of Mycobacterium bovis (Bacillus Calmette-Guérin) on macrophage random migration, chemotaxis, and pinocytosis. Poplack, D.G., Sher, N.A., Chaparas, S.D., Blaese, R.M. Cancer Res. (1976) [Pubmed]
  19. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation. Johnson, W.J., Steplewski, Z., Matthews, T.J., Hamilton, T.A., Koprowski, H., Adams, D.O. J. Immunol. (1986) [Pubmed]
  20. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. Flesch, I.E., Hess, J.H., Huang, S., Aguet, M., Rothe, J., Bluethmann, H., Kaufmann, S.H. J. Exp. Med. (1995) [Pubmed]
  21. Recognition and destruction of Bacillus Calmette-Guerin-infected human monocytes. Molloy, A., Meyn, P.A., Smith, K.D., Kaplan, G. J. Exp. Med. (1993) [Pubmed]
  22. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. Inaba, K., Inaba, M., Naito, M., Steinman, R.M. J. Exp. Med. (1993) [Pubmed]
  23. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. Kuroda, K., Brown, E.J., Telle, W.B., Russell, D.G., Ratliff, T.L. J. Clin. Invest. (1993) [Pubmed]
  24. Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells. Bennett, J.A., Rao, V.S., Mitchell, M.S. Proc. Natl. Acad. Sci. U.S.A. (1978) [Pubmed]
  25. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. Kamijo, R., Le, J., Shapiro, D., Havell, E.A., Huang, S., Aguet, M., Bosland, M., Vilcek, J. J. Exp. Med. (1993) [Pubmed]
  26. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. Turcotte, K., Gauthier, S., Tuite, A., Mullick, A., Malo, D., Gros, P. J. Exp. Med. (2005) [Pubmed]
  27. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine. Chung, M.A., Luo, Y., O'Donnell, M., Rodriguez, C., Heber, W., Sharma, S., Chang, H.R. Cancer Res. (2003) [Pubmed]
  28. Involvement of IFN-gamma in Bacillus Calmette-Guérin-induced but not in tumor-induced sensitization to TNF-induced lethality. Cauwels, A., Brouckaert, P., Grooten, J., Huang, S., Aguet, M., Fiers, W. J. Immunol. (1995) [Pubmed]
  29. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. Uehori, J., Fukase, K., Akazawa, T., Uematsu, S., Akira, S., Funami, K., Shingai, M., Matsumoto, M., Azuma, I., Toyoshima, K., Kusumoto, S., Seya, T. J. Immunol. (2005) [Pubmed]
  30. Enhanced host resistance to transplantable murine lymphosarcoma in Swiss mice by combined immunostimulation with BCG and polyinosinic-polycytidylic acid. Poduval, T.B., Seshadri, M., Sundaram, K. J. Natl. Cancer Inst. (1984) [Pubmed]
  31. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. Lynch, N.R., Salomon, J.C. J. Natl. Cancer Inst. (1979) [Pubmed]
  32. Modulation of cell-mediated alloimmunity by BCG. I. Antagonism and potentiation of immunosuppression caused by cytarabine. Murahata, R.I., Mitchell, M.S. J. Natl. Cancer Inst. (1982) [Pubmed]
  33. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. Kavoussi, L.R., Brown, E.J., Ritchey, J.K., Ratliff, T.L. J. Clin. Invest. (1990) [Pubmed]
  34. The biology and treatment of superficial bladder cancer. Torti, F.M., Lum, B.L. J. Clin. Oncol. (1984) [Pubmed]
WikiGenes - Universities